We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Prostate-specific antigen (PSA) screening is associated with a lower incidence of advanced prostate cancer regardless of statin use, according to a study published online Nov. 24 in JAMA Oncology.